Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Study Overview: Eli Lilly and Company is conducting a global study titled ‘Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease.’ The key objective is to assess the safety and efficacy of donanemab in individuals with early Alzheimer’s disease, aiming to provide a potential treatment for this condition.
Intervention/Treatment: The study tests donanemab, an experimental drug administered intravenously, against a placebo. Donanemab is designed to target and treat early symptomatic Alzheimer’s disease.
Study Design: This is a Phase 3, double-blind, placebo-controlled study. Participants are randomly assigned to receive either donanemab or a placebo, with both participants and investigators unaware of the assignments. The primary goal is to evaluate treatment efficacy.
Study Timeline: The study began on October 10, 2022, with a primary completion date yet to be announced. The last update was submitted on June 27, 2025, indicating ongoing progress and adjustments.
Market Implications: The success of donanemab could significantly impact Eli Lilly’s stock performance, as effective Alzheimer’s treatments are highly sought after. This could also influence investor sentiment positively, given the competitive landscape in Alzheimer’s research.
The study is ongoing, with further details available on the ClinicalTrials portal.